Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica

Journal of Clinical Apheresis

Volumn 27, Issue 4, 2012, Pages 183-192

  Khatri, Bhupendra O ^a   Kramer, John ^a   Dukic, Mary ^a   Palencia, Mauricio ^a   Verre, William ^b  

^a ST LUKE S MEDICAL CENTER   (United States)

^b Verre Young Clinic   (United States)

Author keywords

apheresis; Devic's syndrome; MRI; neuromyelitis optica; plasma exchange; steroid refractory

Indexed keywords

AQUAPORIN 4; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELOOPTIC NEUROPATHY; PLASMAPHERESIS; RECURRENT DISEASE; RETINA NERVE CELL; RETROSPECTIVE STUDY; STEROID REFRACTORY NEUROMYELITIS OPTICA;

ADRENAL CORTEX HORMONES; ADULT; AQUAPORIN 4; AUTOANTIBODIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEUROMYELITIS OPTICA; PLASMA EXCHANGE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84864686900     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21215     Document Type: Article

References (54)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114. (Pubitemid 29442132)
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG,. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112. (Pubitemid 39626806)
3. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H,. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-1461. (Pubitemid 34755161)
4. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H,. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717. (Pubitemid 30390191)
5. Parratt JD, Prineas JW,. Neuromyelitis optica: a demyelinating disease characterized by acute destruction and regeneration of perivascular astrocytes. Mult Scler 2010; 16: 1156-1172.
6. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H,. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-643.
7. Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, Kumanogoh A, Kajiyama K, Yoshikawa H, Sakoda S,. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009; 386: 623-627.
8. Matsushita T, Isobe N, Piao H, Matsuoka T, Ishizu T, Doi H, Masaki K, Yoshiura T, Yamasaki R, Ohyagi Y, Kira J,. Reappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci 2010; 291: 37-43.
9. Weinshenker B,. Western vs optic-spinal MS: two diseases, one treatment? Neurology 2005; 64: 594-595. (Pubitemid 40261884)
10. Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA,. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 5: 110-111. (Pubitemid 43107844)
11. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR,. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477. (Pubitemid 41186945)
12. Bakker J, Metz L,. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004; 31: 265-267. (Pubitemid 38724824)
13. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C,. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
14. Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BA,. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
15. Mandler RN, Ahmed W, Dencoff JE,. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219-1220. (Pubitemid 28473439)
16. Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, Bakshi R,. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63: 957-963. (Pubitemid 44036296)
17. Mok CC, To CH, Mak A, Poon WL,. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol 2008; 35: 172-174.
18. Palace J, Leite MI, Nairne A, Vincent A,. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67: 1016-1017.
19. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, Goto J, Shimizu T, Takatsu M, Sakurai Y, Nakase H, Uesaka Y, Hashida H, Hashimoto K, Komiya T, Tsuji S,. IFN {beta}-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 2010; 75: 1423-1427.
20. Conway D, Cohen JA,. Combination therapy in multiple sclerosis. Lancet Neurol 2010; 9: 299-308.
21. Wingerchuk DM,. Neuromyelitis optica: current concepts. Front Biosci 2004; 9: 834-840. (Pubitemid 39043756)
22. Beck RW, Gal RL,. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 2008; 126: 994-995. (Pubitemid 352008387)
23. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH,. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25: 83-177.
24. Weinshenker BG, O'Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M,. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-886.
25. Cree B,. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 2008; 8: 427-433.
26. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG,. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 143-146.
27. Llufriu S, Castillo J, Blanco Y, Ramio-Torrenta L, Rio J, Valles M, Lozano M, Castella MD, Calabia J, Horga A, Graus F, Montalban X, Saiz A,. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009; 73: 949-953.
28. Magana SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, Shuster E, Kantarci OH, Lucchinetti CF, Weinshenker BG,. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72: 712-717.
29. Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N, Jin K, Aoki M, Fujihara K, Itoyama Y,. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 2009; 72: 1960-1961.
30. Okai AF, Muppidi S, Bagla R, Leist TP,. Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica? Neurol Res 2006; 28: 354-359. (Pubitemid 43765124)
31. Vendrame M, Azizi SA,. The spectrum of neuromyelitis optica: a case of NMO with extensive brain stem involvement. Neurol Res 2007; 29: 32-35. (Pubitemid 46185067)
32. Pittock SJ, Weinshenker BG, Wijdicks EF,. Mechanical ventilation and tracheostomy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 1331-1333. (Pubitemid 39141344)
33. Weinstock-Guttman B, Miller C, Yeh E, Stosic M, Umhauer M, Batra N, Munschauer F, Zivadinov R, Ramanathan M,. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler 2008; 14: 1061-1067.
34. Cassinotto C, Joux J, Chausson N, Smadja D, Cabre P,. Failure of rituximab in relapsing neuromyelitis optica: case report with two-year prospective follow-up. Rev Neurol (Paris) 2008; 164: 394-397. (Pubitemid 351893077)
35. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y,. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13: 128-132. (Pubitemid 46152772)
36. Wingerchuk DM, Weinshenker BG,. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10: 55-66. (Pubitemid 351176056)
37. Wingerchuk DM, Weinshenker BG,. Neuromyelitis Optica. Curr Treat Options Neurol 2005; 7: 173-182. (Pubitemid 40894929)
38. Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P,. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler 2009; 15: 487-492.
39. Antoine JC, Camdessanche JP, Absi L, Lassabliere F, Feasson L,. Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology 2004; 62: 978-980. (Pubitemid 38435791)
40. Miyamoto K, Kusunoki S,. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial 2009; 13: 505-508.
41. Khatri BO, McQuillen MP, Hoffmann RG, Harrington GJ, Schmoll D,. Plasma exchange in chronic progressive multiple sclerosis: a long-term study. Neurology 1991; 41: 409-414.
42. Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J,. Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures. J Clin Apher 2001; 16: 130-133. (Pubitemid 32988800)
43. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG,. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489. (Pubitemid 43958540)
44. Magana SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, Rodriguez M, Thomsen K, Weigand S, Mandrekar J, Linbo L, Lucchinetti CF,. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68: 870-878.
45. Khatri BO,. Vascular access via temporary radial artery catheterization for therapeutic plasma exchange. J Clin Apher 2003; 18: 134. (Pubitemid 37280786)
46. Yacopetti N,. Central venous catheter-related thrombosis: a systematic review. J Infus Nurs 2008; 31: 241-248.
47. Balcer LJ,. Clinical outcome measures for research in multiple sclerosis. J Neuroophthalmol 2001; 21: 296-301. (Pubitemid 34027533)
48. Sergott RC,. Optical coherence tomography: measuring in-vivo axonal survival and neuroprotection in multiple sclerosis and optic neuritis. Curr Opin Ophthalmol 2005; 16: 346-350. (Pubitemid 41735824)
49. Green AJ, Cree BA,. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 2009; 80: 1002-1005.
50. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V,. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76: 2017-2023.
51. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, Garcia-Layana A, Bejarano B, Villoslada P,. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 2007; 68: 1488-1494. (Pubitemid 46685919)
52. Borberg H,. Quo vadis haemapheresis. Current developments in haemapheresis. Transfus Apher Sci 2006; 34: 51-73. (Pubitemid 43220389)
53. Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ,. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68: 473-479.
54. Kingwell E, Koch M, Leung B, Isserow S, Geddes J, Rieckmann P, Tremlett H,. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010; 74: 1822-1826.